Origdata

Our research aims to comprehensively assess the potential effects of genetic lipid-lowering medications on a range of lung-related diseases (LRD), including small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF),pulmonary edema(PE), and pneumonia. We strive to understand the possible impact of genetic lipid-lowering medications on the risk of developing these specific lung diseases. This study is anticipated to offer novel insights into the influence of genetically regulated lipid-lowering medications onLRD.

本研究旨在全面评估遗传性降脂药物对一系列肺部相关疾病（lung-related diseases, LRD）的潜在影响，涵盖小细胞肺癌（small cell lung cancer, SCLC）、非小细胞肺癌（non-small cell lung cancer, NSCLC）、慢性阻塞性肺疾病（chronic obstructive pulmonary disease, COPD）、特发性肺纤维化（idiopathic pulmonary fibrosis, IPF）、肺水肿（pulmonary edema, PE）以及肺炎。本研究旨在阐明遗传性降脂药物对上述特定肺部疾病的发病风险的潜在作用。本研究有望为基因调控的降脂药物对肺部相关疾病的影响提供全新的研究视角。